H.B. Fuller is in the middle of a portfolio and efficiency transition: it is using Quantum Leap restructuring to push margins above 20% while moving further into higher-growth medical adhesives through the pending AMS acquisition. AMS shareholder approval was already secured in August, and the company expects the deal to close before year-end.
| Metric | Q3 FY2026 | Comparison / expectation |
|---|---|---|
| Net revenue | $938.2M | $892.0M last year; ~$940.4M published consensus |
| Organic revenue growth | 4.4% | 4.4% last year |
| Adjusted EPS | $1.52 | $1.26 last year; ~$1.45 consensus |
| Adjusted EBITDA | $186.7M | $170.6M last year; +9% |
| Adjusted EBITDA margin | 19.9% | 19.1% last year |
| FY2026 adjusted EBITDA guide | $655M–$670M | Prior $650M–$675M range |
| FY2026 adjusted EPS guide | $4.70–$4.85 | Prior $4.60–$4.90 range |
The earnings beat came from margin execution, not stronger volume. Adjusted EPS of $1.52 exceeded the roughly $1.45 consensus, while revenue of $938 million was modestly below the roughly $940 million published estimate. Pricing increased revenue 7.4% and more than offset lower volume, producing 4.4% organic growth. 〔0〕 The key business improvement was profitability: adjusted gross margin rose 120 basis points to 33.5%, and adjusted EBITDA margin reached a record 19.9%. 〔1〕
The quarter supports the restructuring story across the portfolio. Adjusted EBITDA grew in all three global business units, with margins improving in Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Building Adhesive Solutions. That makes the margin progress more credible than a result driven by one isolated segment, although the underlying demand picture remains less impressive because volume was still down low-single digits.
Guidance was effectively reaffirmed, not materially raised. The new full-year EBITDA and EPS ranges are narrower than the prior ranges but have essentially unchanged midpoints, while the revenue outlook remains mid-single-digit reported growth and low-single-digit organic growth. The company also increased its expected foreign-exchange contribution to approximately 2%, which helps reported revenue but does not change the underlying demand signal. This is therefore a modest operating execution win rather than a major reset to the 2026 outlook.
Cash generation improved, but working capital is absorbing cash ahead of the AMS deal. Year-to-date operating cash flow rose 17% to $183 million, while net leverage fell to 3.0x from 3.3x a year earlier. However, working capital increased to 18.5% of annualized revenue, up 150 basis points, as Fuller built inventory for Quantum Leap and supply continuity. 〔2〕
Bottom line: This was a profitability-led beat: pricing and restructuring are working, but volume remains soft and the full-year outlook is largely unchanged. The result modestly strengthens the margin-improvement story while leaving the AMS closing and integration as the next major business test.
Read the original 8-K on SEC EDGAR ↗